AbolerIS Pharma develops immuno-modulators as treatments for transplant rejection, graft-versus-host disease, and auto-immune diseases.
AbolerIS Pharma has raised $29.2M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
AbolerIS Pharma's investors include Sound Bioventures, Newton Biocapital, SFPIM, Criteria Bio Ventures, Sambrinvest.
AbolerIS Pharma is headquartered in Nantes, France.
AbolerIS Pharma develops immuno-modulators as treatments for transplant rejection, graft-versus-host disease, and auto-immune diseases.
AbolerIS Pharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AbolerIS Pharma — Funding & Investors." VCBacked, September 18, 2023, https://www.vcbacked.co/company/aboleris-pharma. Accessed August 1, 2026.
VCBacked. (2023). AbolerIS Pharma — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/aboleris-pharma
{{cite web |title=AbolerIS Pharma — Funding & Investors |url=https://www.vcbacked.co/company/aboleris-pharma |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated